Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Tsapakos

Diagnostic Radiology Lebanon, NH Medical Doctor

NPI 1952321036 CMS profile 223953

1 Medical Center Dr, Department Of Radiology, Lebanon, NH 03756

Open in the dashboard

General payments

$210,510

105 records reported · program years 2019–2025

Research payments

$189,386

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$28,866 paid to institutions, not to them · program years 2020–2023

Through program year 2025, Michael Tsapakos of Lebanon, NH is reported in the CMS Open Payments database as having received $210,510 across 105 general payments and $189,386 in research payments paid to them. Separately, studies naming them as principal investigator received $28,866 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,430 7
2025 Research $7,340 4
2024 General $26,970 11
2024 Research $42,650 3
2023 General $5,205 6
2023 Research $26,803 2
2022 Research $32,695 1
2021 General $86,405 42
2021 Research $41,683 2
2020 General $47,845 20
2020 Research $38,216 2
2019 General $13,655 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Tsapakos
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Michael Tsapakos were reported at $30,430. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Michael Tsapakos Diagnostic Radiology median Middle half National median
2019 $13,655 $108 $29–$318 $163
2020 $47,845 $65 $21–$252 $114
2021 $86,405 $92 $24–$292 $132
2022 $0 $104 $29–$294 $149
2023 $5,205 $110 $29–$337 $160
2024 $26,970 $113 $30–$356 $164
2025 $30,430 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $147,905 81 payments
  2. Pfizer Inc. $35,475 18 payments
  3. Seattle Genetics, Inc. $27,130 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $210,510 105 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $116,740 48 payments
  2. PREVNAR 20 $34,035 17 payments
  3. LENVIMA $29,920 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $183,203 7 payments
  2. Regeneron Pharmaceuticals, Inc. $3,340 3 payments
  3. Genentech, Inc. $2,108 1 payment
  4. Hexal AG $735 3 payments

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$161,472

Of which drugs: $304

Medicare patients

1,792

Average age 77

Services billed

4,487

953 women, 839 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 55%
Diabetes 41%
Chronic kidney disease 31%
Heart failure 29%
Depression 29%
Atrial fibrillation 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 13 1,450 $155

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record